Status:
COMPLETED
A Study to Assess the Drug-drug Interaction of BMS-963272 and Rosuvastatin
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Healthy Participants
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
Phase 1 study that assesses the effect of BMS-963272 on exposure of rosuvastatin in healthy participants
Eligibility Criteria
Inclusion
- For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
- Healthy participants, as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations
- Women must not be of childbearing potential (WNOCBP)
- Women and men must agree to follow instructions for methods of contraception
Exclusion
- Any significant acute or chronic medical condition that presents a potential risk to the participant and/or may compromise the objectives of the study.
- Any major surgery within 4 weeks of study drug administration
- Any blood transfusion or donation of blood to a blood bank or in a clinical study within 4 weeks of study drug administration
- Previous treatment with BMS-963272
- Participants who smoke, as well as, those who have stopped smoking less than 6 months prior to day 1
- Other protocol-defined inclusion/exclusion criteria could apply
Key Trial Info
Start Date :
October 8 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 3 2020
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT04124003
Start Date
October 8 2019
End Date
January 3 2020
Last Update
March 10 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
PRA Health Sciences - Salt Lake
Salt Lake City, Utah, United States, 84124